Empowered Funds LLC Purchases Shares of 11,714 Elanco Animal Health Incorporated (NYSE:ELAN)

Empowered Funds LLC purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,714 shares of the company’s stock, valued at approximately $142,000.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after purchasing an additional 65,303 shares in the last quarter. Atom Investors LP boosted its position in shares of Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock valued at $5,081,000 after purchasing an additional 261,559 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Elanco Animal Health by 19.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock valued at $58,875,000 after purchasing an additional 646,522 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock valued at $5,349,000 after purchasing an additional 45,795 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ELAN. Stifel Nicolaus dropped their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Morgan Stanley dropped their price target on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partners assumed coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Finally, UBS Group assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They set a “buy” rating and a $18.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Trading Down 1.0 %

NYSE:ELAN opened at $11.02 on Friday. Elanco Animal Health Incorporated has a one year low of $10.77 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company’s 50-day simple moving average is $11.80 and its 200 day simple moving average is $13.10. The firm has a market capitalization of $5.45 billion, a P/E ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.